Consequently, the integration of CTLA-4/PD-1 inhibitors with small-molecule agents, antibodies, cellular therapies, and vaccines is emerging as a promising strategy for melanoma brain metastases (MBM) and warrants validation through prospective clinical trials incorporating stratified brain metastasis cohorts or dedicated MBM arms (see Table 4). Here, CTLA4 is linked to melanoma.